{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:10:46Z","timestamp":1779210646479,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-02943-0","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:55:30Z","timestamp":1775469330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic inertia and lipid-lowering treatment modification after acute coronary syndrome: a longitudinal real-world study using a lagged decision\u2013outcome design"],"prefix":"10.1186","volume":"25","author":[{"given":"Qiyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaofeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"12","key":"2943_CR1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","volume":"136","author":"F Crea","year":"2017","unstructured":"Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment. Circulation. 2017;136(12):1155\u201366.","journal-title":"Circulation"},{"issue":"8934","key":"2943_CR2","first-page":"1383","volume":"344","author":"Randomised trial of cholesterol lowering","year":"1994","unstructured":"Randomised trial of cholesterol lowering. in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20139.","journal-title":"Lancet"},{"issue":"13","key":"2943_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138.","journal-title":"JAMA"},{"issue":"15","key":"2943_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"14","key":"2943_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"key":"2943_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2025.05.029","volume":"253","author":"S Sedrakyan","year":"2025","unstructured":"Sedrakyan S, Nadeem B, Gaughran D, Sinauridze A, Georgy A, Sally H, et al. Bridging Gaps in LDL-C Management: Utilization of Lipid-Lowering Therapies, Gender Disparities, and the Impact of Cardiology Visits on Secondary Prevention. Am J Cardiol. 2025;253:1\u20139.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2943_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"2943_CR8","doi-asserted-by":"crossref","unstructured":"Correction to, NLA\/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2023;148(7):e5. \/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/. 2018 AHA\/ACC\/AACVPR\/AAPA.","DOI":"10.1161\/CIR.0000000000001172"},{"issue":"25","key":"2943_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"18","key":"2943_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"2943_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"4","key":"2943_CR12","first-page":"299","volume":"6","author":"MF Piepoli","year":"2017","unstructured":"Piepoli MF, Corr\u00e0 U, Dendale P, Frederix I, Prescott E, Schmid JP, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur Heart J Acute Cardiovasc Care. 2017;6(4):299\u2013310.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"12","key":"2943_CR13","doi-asserted-by":"publisher","first-page":"e009399","DOI":"10.1161\/CIRCOUTCOMES.122.009399","volume":"15","author":"K Nasir","year":"2022","unstructured":"Nasir K, Salami JA. Therapeutic Inertia in Lipid-Lowering Treatment Intensification: Digital Tools and Performance Management to the Rescue? Circ Cardiovasc Qual Outcomes. 2022;15(12):e009399.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2943_CR14","doi-asserted-by":"publisher","first-page":"18936","DOI":"10.1038\/s41598-022-21916-8","volume":"12","author":"X Yan","year":"2022","unstructured":"Yan X, Mudiganti S, Husby H, Hudnut A, Gbotoe M, Jones JB. Medication non-adherence and therapeutic inertia independently contribute to poor disease control for cardiometabolic diseases. Sci Rep. 2022;12(1):18936.","journal-title":"Sci Rep"},{"key":"2943_CR15","unstructured":"2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1\u201329."},{"key":"2943_CR16","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.","journal-title":"Front Pharmacol"},{"key":"2943_CR17","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1016\/j.jacc.2014.02.606","volume":"63","author":"B Andrus","year":"2014","unstructured":"Andrus B, Lacaille D. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63:2886. (25 Pt A).","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2943_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4997\/JRCPE.2017.212","volume":"47","author":"S Hadjiphilippou","year":"2017","unstructured":"Hadjiphilippou S, Ray KK. Evolocumab and clinical outcomes in patients with cardiovascular disease. J R Coll Physicians Edinb. 2017;47(2):153\u20135.","journal-title":"J R Coll Physicians Edinb"},{"issue":"10106","key":"2943_CR19","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962\u201371.","journal-title":"Lancet"},{"issue":"16","key":"2943_CR20","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"P Gaba","year":"2023","unstructured":"Gaba P, O\u2019Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023;147(16):1192\u2013203.","journal-title":"Circulation"},{"issue":"1","key":"2943_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12872-022-02618-5","volume":"22","author":"L Zhu","year":"2022","unstructured":"Zhu L, Zheng J, Gao B, Jin X, He Y, Zhou L, et al. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels. BMC Cardiovasc Disord. 2022;22(1):171.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02943-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02943-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02943-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:40:30Z","timestamp":1779208830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02943-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2943"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02943-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The Fifth People\u2019s Hospital of Shanghai, Fudan University and conducted in accordance with the Declaration of Helsinki. As a retrospective study, informed consent was waived by the Ethics Committee due to the use of anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual person\u2019s data or images are included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}